Ivosidenib or Enasidenib Combined with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation Is Safe, Effective, and Leads to MRD-Negative Complete Remissions
Year: 2018
Type: conference-abstract
Source: Blood
Authors: Eytan M. Stein, Courtney D. DiNardo, Amir T. Fathi, Alice S. Mims, Keith W. Pratz, Michael R. Savona, Anthony S. Stein, Richard M. Stone, Eric S. Winer, Christopher S. Seet, Hartmut Döhner, Daniel A Pollyea, James K McCloskey, Olatoyosi Odenike, Bob Lowenberg, Gert J. Ossenkoppele, Prapti A. Patel, Mikhail Roshal, Frederik Lersch, Salah Nabhan, Sung Choe, Hongfang Wang, Lei Hua, Caroline Almon, Michael Cooper, Martin S. Tallman
Institutions: Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Massachusetts General Hospital, The Ohio State University Wexner Medical Center, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Vanderbilt University, Vanderbilt University Medical Center, City Of Hope National Medical Center, Dana-Farber Cancer Institute, Ronald Reagan UCLA Medical Center, UCLA Medical Center, University Hospital Ulm, University of Colorado Anschutz, University of Colorado Denver, Hackensack University Medical Center, University of Chicago Medicine Comprehensive Cancer Center, Erasmus MC, Cancer Center Amsterdam, Amsterdam UMC Location Vrije Universiteit Amsterdam, The University of Texas Southwestern Medical Center, Agios Pharmaceuticals (United States)
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2906855438